Psilocybin Shows Promise for Those Ready to Break Free from Nicotine

BALTIMORE – Researchers at Johns Hopkins University have published findings from a pilot randomized clinical trial that points to potential advantages of psilocybin-assisted therapy over standard nicotine replacement for helping adults quit cigarettes.

Published in JAMA Network Open, the study compared nicotine patches to psilocybin as smoking cessation tools. At the six-month mark, participants who received just one dose of psilocybin had more than six times greater odds of remaining cigarette-free than those who relied on the nicotine substitute.

The trial, led by Dr. Matthew Johnson, a professor of psychiatry at Johns Hopkins, enrolled 82 adult smokers who had a mean age of about 48, reported a median of six previous quit attempts and had expressed a clear intention to quit. They were randomly divided into two groups, creating what researchers describe as the first randomized comparison between a psychedelic intervention and a standard tobacco addiction treatment.

Both groups underwent the same foundation of care. All participants completed a 13-week cognitive behavioral therapy program specifically designed for smoking cessation. Those in the psilocybin group ingested a relatively high dose of pure psilocybin (about 30 mg per 70 kg of body weight) in a controlled environment. While under the influence, they lay in a room wearing eye shades and listening to soft music, though the overall experience was described by Johnson as “self-directed.”

By six months, 40.5% of participants in the psilocybin group had remained abstinent. In the nicotine patch group, that figure was 10%.

What makes these findings particularly notable is the biology behind them. Unlike standard smoking cessation treatments, psilocybin does not target nicotine receptors, making it “a very different treatment approach from just trying to replace or sort of mimic the drug that’s being misused,” according to Dr. Brian Barnett, an addiction psychiatrist at the Cleveland Clinic Lerner College of Medicine who was not involved in the study.

Researchers believe psilocybin works by influencing psychological systems, changing self-perception, and shifting behaviors, rather than directly addressing nicotine withdrawal or altering how nicotine acts in the body. Biologically, psychedelics temporarily alter brain communication and may promote neuroplasticity – the brain’s ability to form new connections. The therapy, in other words, may give the brain the flexibility to break free from deeply ingrained behavioral grooves rather than merely suppressing withdrawal symptoms.

The Johns Hopkins psilocybin smoking trial is the kind of data point that the psychedelics industry has needed: clean methodology, a head-to-head comparison against an established standard of care, and results significant enough to command peer-reviewed publication in a major medical journal.

For investors and operators watching the addiction treatment space, this study adds a credible plank to a platform that has so far been built mostly around depression and PTSD. Tobacco kills approximately 480,000 Americans annually, a figure that dwarfs mortality from all other substance use disorders combined. If psilocybin-assisted therapy proves out across larger populations, the addressable market for this application alone is enormous, and the clinical urgency is unambiguous.